Cooper Companies (COO) Expected to Announce Earnings on Thursday

Cooper Companies (NASDAQ:COO) is projected to release its Q2 2026 results after the market closes on Thursday, June 4th. Analysts expect Cooper Companies to post earnings of $1.10 per share and revenue of $1.0548 billion for the quarter. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, June 4, 2026 at 5:00 PM ET.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.07. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the prior year, the business earned $0.92 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. On average, analysts expect Cooper Companies to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $60.80 on Thursday. The firm’s 50 day moving average price is $66.38 and its 200-day moving average price is $75.02. Cooper Companies has a twelve month low of $58.89 and a twelve month high of $89.83. The company has a quick ratio of 0.79, a current ratio of 1.34 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $11.86 billion, a PE ratio of 30.10, a price-to-earnings-growth ratio of 1.60 and a beta of 0.89.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp grew its holdings in Cooper Companies by 2.4% during the 4th quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock valued at $720,736,000 after buying an additional 207,195 shares in the last quarter. Wellington Management Group LLP grew its holdings in Cooper Companies by 332.9% during the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after buying an additional 4,756,178 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Cooper Companies by 58.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock valued at $494,123,000 after buying an additional 2,231,568 shares in the last quarter. Sustainable Growth Advisers LP grew its holdings in Cooper Companies by 22.1% during the 3rd quarter. Sustainable Growth Advisers LP now owns 4,132,535 shares of the medical device company’s stock valued at $283,327,000 after buying an additional 747,476 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Cooper Companies by 98.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after buying an additional 1,683,561 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

COO has been the topic of a number of recent analyst reports. Needham & Company LLC raised their target price on shares of Cooper Companies from $99.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Barclays raised their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, March 6th. Citigroup decreased their target price on shares of Cooper Companies from $88.00 to $87.00 and set a “neutral” rating on the stock in a research note on Friday, March 6th. Finally, The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.93.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.